The purposes of this study were to investigate the incidence of lymphedema in patients with breast cancer during and after adjuvant treatment with docetaxel, doxorubicin, and cyclophosphamide (TAC), to identify predictors for development of lymphedema, and to describe consequences in daily life in relation to lymphedema.
This is a prospective study with measurements before chemotherapy (T0), during chemotherapy before cycle 2 (T1), cycle 4 (T2), and 1 month after completion of treatment (T3). Volume change was monitored using tape measurements. Lymphedema was defined as ≥ 10% volume difference. Linear mixed-effect models were estimated to analyze differences in arm volume and consequences in daily life (total score and domain scores of the Lymph-International Classification of Functioning (ICF) questionnaire) over time and to identify treatment and patient characteristics as predictors for changes in volume.
Forty-eight patients completed all measurements. Volume did not change during TAC treatment. One month after treatment, volume was significantly increased compared to T0-T2, and 12 patients (25%) had developed lymphedema. Axillary lymph node dissection was associated with lymphedema (ES 2.9, 95% CI 0.02–5.7; p < 0.05). In patients with and without lymphedema, 1 month after completion (T3), the Lymph-ICF questionnaire showed significant limitations in physical function compared to T0-T2. In patients with lymphedema at T3, a significant association between volume and total score on the Lymph-ICF questionnaire on physical function and mobility activities was observed.
One month after treatment in 12 patients (25%), volume difference increased over 10%. Axillary lymph node dissection was predictive for development of lymphedema. All patients, but more patients with lymphedema, perceived difficulties in activities in daily life after treatment.
Viehoff PB et al (2015) Development of consensus International Classification of Functioning, Disability and Health (ICF) core sets for lymphedema. Lymphology 48(1):38–50 PubMed
Moffat C, Doherty D, Morgan P (2006) In: Framework TL (ed) Best practice for the management of lymphoedema. International consensus. MEP. Ltd, London
Zomkowski K et al (2017) Physical symptoms and working performance in female breast cancer survivors: a systematic review. Disabil Rehabil. https://doi.org/10.1080/09638288.2017.1300950
Hidding JT et al (2014) Treatment related impairments in arm and shoulder in patients with breast cancer: a systematic review . PLoS One. 9(5)
Hugenholtz-Wamsteker W et al (2016) The effect of docetaxel on developing oedema in patients with breast cancer: a systematic review. Eur J Cancer Care (Engl) 25(2):269–279 CrossRef
http://richtlijnendatabase.nl/richtlijn/breast_cancer/breast_cancer.html. 2012, IKNL and KiMS
Fleiss JL, Levin B, Paik MC (2003) Statistical methods for rates and proportions, 3rd edn. Wiley, New York
Bromham N et al (2017) Axillary treatment for operable primary breast cancer. Cochrane Database Syst Rev 1:Cd004561 PubMed
Czerniec SA et al (2010) Assessment of breast cancer-related arm lymphedema—comparison of physical measurement methods and self-report. Cancer Investig 28(1):54–62 CrossRef
Testa A, Iannace C, Di Libero L (2014) Strengths of early physical rehabilitation programs in surgical breast cancer patients: results of a randomized controlled study. Eur J Phys Rehabil Med 50(3):275–284 PubMed
van Waart H et al (2015) Effect of low-intensity physical activity and moderate- to high-intensity physical exercise during adjuvant chemotherapy on physical fitness, fatigue, and chemotherapy completion rates: results of the PACES randomized clinical trial. J Clin Oncol 33(17):1918–1927 CrossRefPubMed
Furmaniak Anna CA (2016) Exercise for women receiving adjuvant therapy for breast cancer . Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD005001.pub3
Hickey BE, Francis DP, and Lehman M (2013) Sequencing of chemotherapy and radiotherapy for early breast cancer . Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD005212.pub3
Miller CL et al (2013) A novel, validated method to quantify breast cancer-related lymphedema (BCRL) following bilateral breast surgery. Lymphology 46(2):64–74 PubMed
- Changes in volume and incidence of lymphedema during and after treatment with docetaxel, doxorubicin, and cyclophosphamide (TAC) in patients with breast cancer
Janine T. Hidding
Carien H. G. Beurskens
Philip J. van der Wees
Wilmy C. A. M. Bos
Maria W. G. Nijhuis-van der Sanden
Hanneke W. M. van Laarhoven
- Springer Berlin Heidelberg
Neu im Fachgebiet Onkologie
Mail Icon II